The Protective Effect of New Carnosine-Hyaluronic Acid Conjugate on the Inflammation and Cartilage Degradation in the Experimental Model of Osteoarthritis
Authors:
- Rosalba SiracusaRSRosalba Siracusa
- Daniela ImpellizzeriDaniela Impellizzeri
- Marika CordaroMarika Cordaro
- Alessio F. PeritoreAPAlessio F. Peritore
- Enrico GugliandoloEnrico Gugliandolo
- Ramona D’amicoRDRamona D’amico
- Roberta FuscoRoberta Fusco
- Rosalia CrupiRosalia Crupi
- Enrico RizzarelliEnrico Rizzarelli
- Salvatore CuzzocreaSalvatore Cuzzocrea
- Susanna VaccaroSVSusanna Vaccaro
- Mariafiorenza PulicettaMPMariafiorenza Pulicetta
Open Access
- 15 February 2020
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 10 (4) , 1324
Abstract
Osteoarthritis (OA) is a disease that currently has no cure. There are numerous studies showing that carnosine and hyaluronic acid (HA) have a positive pharmacological action during joint inflammation. For this reason, the goal of this research was to discover the protective effect of a new carnosine conjugate with hyaluronic acid (FidHycarn) on the inflammatory response and on the cartilage degradation in an in vivo experimental model of OA. This model was induced by a single intra-articular (i.ar.) injection of 25 µL of normal saline with 1 mg of monosodium iodoacetate solution (MIA) in the knee joint of rats. MIA injection caused histological alterations and degradation of the cartilage, as well as behavioral changes. Oral treatment with FidHycarn ameliorated the macroscopic signs, improved thermal hyperalgesia and the weight distribution of the hind paw, and decreased histological and radiographic alterations. The oxidative damage was analyzed by evaluating the levels of nitrotyrosine and inducible nitric oxide synthase (iNOS) that were significantly reduced in FidHycarn rats. Moreover, the levels of pro-inflammatory cytokines and chemokines were also significantly reduced by FidHycarn. Therefore, for the first time, the effectiveness of oral administration of FidHycarn has been demonstrated in an osteoarthritis model. In conclusion, the new FidHycarn could represent an interesting therapeutic strategy to combat osteoarthritis.Keywords
All Related Versions
This publication has 48 references indexed in Scilit:
- Involvement of H-Ras and reactive oxygen species in proinflammatory cytokine-induced matrix metalloproteinase-13 expression in human articular chondrocytesArchives of Biochemistry and Biophysics, 2011
- Redox-control of matrix metalloproteinase-1: A critical link between free radicals, matrix remodeling and degenerative diseaseRespiratory Physiology & Neurobiology, 2010
- Developments in the scientific understanding of osteoarthritisArthritis Research & Therapy, 2009
- Cartilage homeostasis in health and rheumatic diseasesArthritis Research & Therapy, 2009
- The increased swelling and instantaneous deformation of osteoarthritic cartilage is highly correlated with collagen degradationArthritis & Rheumatism, 2000
- Evidence Linking Chondrocyte Lipid Peroxidation to Cartilage Matrix Protein DegradationJournal of Biological Chemistry, 2000
- Evidence for altered synthesis of type II collagen in patients with osteoarthritis.Journal of Clinical Investigation, 1998
- Effects of disease modifying antirheumatic drugs(DMARDs) and DEX on IL-1.BETA. and IL-6 production by IL-1.BETA. stimulated synovial culture cells.Nihon Ika Daigaku Zasshi, 1996
- METHOTREXATE ACTION IN RHEUMATOID ARTHRITIS: STIMULATION OF CYTOKINE INHIBITOR AND INHIBITION OF CHEMOKINE PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLSRheumatology, 1995
- The relative toxicity of alternative therapies for rheumatoid arthritis: Implications for the therapeutic progressionSeminars in Arthritis and Rheumatism, 1993